Factor VIII (FVIII) replacement therapy is the foundation of treatment in hemophilia A and is
effective unless a patient develops an alloantibody (inhibitor) against exogenous FVIII …

The standard therapy for patients with haemophilia is prophylactic treatment with
replacement factor VIII (FVIII) or factor IX (FIX). Patients who develop inhibitors against …

Neutralizing antibodies (inhibitors) toward factor VIII form a severe complication in
nonsevere hemophilia A, profoundly aggravating the bleeding pattern. Identification of high …

1School of Medicine, Cardiff University, University Hospital of Wales, Wales, 2Royal
Hospital for Sick Children, Glasgow, 3The London School of Medicine and Dentistry, Royal …

The revised UKHCDO factor (F) VIII/IX Inhibitor Guidelines (2000) are presented. A schema
is proposed for inhibitor surveillance, which varies according to the severity of the …

The formation of alloantibodies against factor VIII (FVIII) or factor IX (FIX) is the most severe
complication of replacement therapy in patients with haemophilia. In the last decade, genetic …

Abstract Treatment of patients with hemophilia A and B has undergone significant advances
during the past 2 decades. However, despite these advances, the development of …

Although immune tolerance induction (ITI) has been used for 30 years to eliminate inhibitors
and restore normal factor pharmacokinetics in patients with hemophilia, there is a paucity of …

Background: Previous studies of the development of inhibitors and their impact on mortality
have been small. Objectives: To examine the development of inhibitors in people with …

Mild haemophilia is defined by factor levels between 0.05 and 0.40 IU/mL and is
characterised by traumatic bleeds. Major issues associated with mild haemophilia are that it …